Christine Kowalski Net Worth

Christine Kowalski biography

Christine R. Kowalski serves as Chief Operating Officer, Executive Vice President of the Company. Ms. Kowalski has served as our Executive Vice President and Chief Operating Officer since February 2020, and previously as our Chief Operations Officer since October 2018. From April 2015 to September 2015, Ms. Kowalski served as Vice President, Supply Chain Strategy for Johnson & Johnson, a medical device and pharmaceutical company, where she oversaw strategy and performance management for their collective supply chain. From December 2013 to February 2014, she served as Executive Vice President, Global Operations for RTI Surgical, Inc., a surgical implant company, where she delivered a series of strategic product launches. From December 2011 to June 2013, she served as Senior Vice President, Global Operations and Supply Chain of American Medical Systems Holdings, Inc., the medical devices business for Endo Healthcare Solutions, a urology implant company. Ms. Kowalski served as Senior Vice President, Operations for ev3 Inc., a peripheral and neurovascular company, from March 2010 until September 2010 through its acquisition by Covidien. From 1992 to 2010, Ms. Kowalski held a variety of operational leadership positions at Guidant Corporation, through its acquisition by Boston Scientific Corporation in 2006, where she was most recently the Group Vice President and General Manager, Operations for their Vascular Access business.

What is the salary of Christine Kowalski?

As the Chief Operating Officer e Executive Vice President of Intersect ENT Inc, the total compensation of Christine Kowalski at Intersect ENT Inc is $1,263,240. There are 3 executives at Intersect ENT Inc getting paid more, with Thomas West having the highest compensation of $7,206,100.

How old is Christine Kowalski?

Christine Kowalski is 63, she's been the Chief Operating Officer e Executive Vice President of Intersect ENT Inc since 2020. There are 2 older and 11 younger executives at Intersect ENT Inc. The oldest executive at Intersect ENT Inc is Frederic Moll, 68, who is the Independent Director.

What's Christine Kowalski's mailing address?

Christine's mailing address filed with the SEC is C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Intersect ENT Inc

Over the last 10 years, insiders at Intersect ENT Inc have traded over $22,664,783 worth of Intersect ENT Inc stock and bought 58,846 units worth $713,631 . The most active insiders traders include Rick D Anderson, Lisa D Earnhardt e W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of $344,556. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth $9,000.

What does Intersect ENT Inc do?

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.

Intersect ENT Inc executives and stock owners

Intersect ENT Inc executives and other stock owners filed with the SEC include:

• Thomas West,
  President, Chief Executive Officer, Director
• Kieran Gallahue,
  Non-Executive Chairman of the Board
• Richard Meier,
  Chief Financial Officer, Executive Vice President
• Christine Kowalski,
  Chief Operating Officer, Executive Vice President
• Gwen Carscadden,
  Chief People Officer
• Thomas A. West,
  Pres, CEO & Director
• Richard A. Meier,
  Exec. VP & CFO
• Cynthia Lucchese,
  Independent Director
• Dana Mead,
  Independent Director
• William Vernon,
  Independent Director
• Teresa Kline,
  Independent Director
• Frederic Moll,
  Independent Director
• Patrick A. Broderick,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Reyna M. Fernandez,
  Chief Human Resource Officer
• Drake R. Parker,
  Advisor of Strategic Initiatives
• Jeryl L Hilleman,
  Chief Financial Officer
• Lisa D Earnhardt,
  
• Casey M Tansey,
  Director
• Amy Wolbeck,
  See Remarks
• Susan P Stimson,
  Vice President, Marketing
• Richard E Kaufman,
  See Remarks
• Drake R. Parker,
  Chief Business Officer
• David Aaron Lehman,
  EVP & General Counsel
• Neil A Hattangadi,
  
• Robert H Jr Binney,
  Chief Commercial Officer
• Rick D Anderson,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Clercq Casper L. De,
  Director
• Sciences Ii L P Pinto Techn...,
  
• Perkins Caufield & Byers Xi...,
  
• James Stambaugh,
  VP, Clinical and Reimbursement
• Chas Mc Khann,
  Chief Commercial Officer
• Mark J Fletcher,
  Director
• Management Group Ix, L.L.C....,
  
• Venture Partners Xi, Lp Nor...,
  
• W Anthony Vernon,
  
• Reyna M Fernandez,
  Chief Human Resource Officer
• Patrick A Broderick,
  EVP, GC & Corporate Secretary
• Elisabeth Sandoval,